Distalmotion raises $150m to accelerate FDA approval and clinical experience of Dexter, its cutting-edge robotic platform.
https://www.distalmotion.com/dexter-series-e-90m-to-make-sense-of-robotic-surgery/ Image credits: Distalmotion
Dexter Series E: $90M to Make Sense of Robotic Surgery
https://www.distalmotion.com/dexter-series-e-90m-to-make-sense-of-robotic-surgery/Image credits: Distalmotion
Distalmotion’s surgical robot is ready for clinical use
Distalmotion, a Swiss-based medical device company, received ...
Distalmotion – Dieser Gründer entwickelt einen Roboter für Operationen
Distalmotion-Chef Michael Friedrich über Anwendungsmöglichkeiten des Roboterarms. ...
Distalmotion – Dexter successful validation brings Distalmotion surgical robot one-step closer to commercialization
Dexter validation confirms Distalmotion surgical robot is ...
Distalmotion – Dexter wins iF Design Award 2020: A surgical robot from Vaud, on the world design podium
Dexter’s unique approach to robotics has been ...
Distalmotion – Interview with with Prof. David Jayne
A major milestone towards Dexter's go-to-market was ...
As ‘Robot Wars’ Kick-In, Is Robotic Surgery Ripe for an ‘iPhone Moment’?
Designs are needed to reduce the complexity ...
Interview with Michael Friedrich, Distalmotion CEO
Roger Smith, PhD of AdventHealth Nicholson ...